Continuous ghrelin infusion attenuates the postoperative inflammatory response in patients with esophageal cancer
- PDF / 952,640 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 51 Downloads / 172 Views
ORIGINAL ARTICLE
Continuous ghrelin infusion attenuates the postoperative inflammatory response in patients with esophageal cancer Kotaro Yamashita1 · Kazuyoshi Yamamoto1 · Akihiro Takata1 · Yasuhiro Miyazaki1 · Takuro Saito1 · Koji Tanaka1 · Tomoki Makino1 · Tsuyoshi Takahashi1 · Yukinori Kurokawa1 · Makoto Yamasaki1 · Masayuki Mano2 · Kiyokazu Nakajima1 · Hidetoshi Eguchi1 · Yuichiro Doki1 Received: 19 March 2020 / Accepted: 24 August 2020 © The Japan Esophageal Society 2020
Abstract Purpose The aim of this study was to clarify whether ghrelin infusion is useful for suppressing inflammatory responses after esophagectomy. Methods A phase I study of ghrelin administration after esophagectomy was performed in 20 patients with esophageal cancer. The anti-inflammatory effect of ghrelin was compared with 20 consecutive patients who did not receive ghrelin infusion. Additionally, 10 patients with intermittent infusion for 10 days were compared with 10 patients with continuous infusion for 5 days. The primary endpoint was the duration of systemic inflammatory response syndrome (SIRS). Secondary endpoints included postoperative complications, serum C-reactive protein (CRP), interleukin-6 (IL-6), and growth hormone (GH) levels. Results No adverse events of ghrelin administration occurred. Patients with ghrelin infusion had higher plasma ghrelin levels on postoperative day (POD) 3 (p = 0.003) and shorter SIRS duration (p = 0.007) than patients without ghrelin infusion. Although SIRS duration was similar (p = 0.19), patients with continuous ghrelin infusion had significantly higher plasma ghrelin (p
Data Loading...
